Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
P 2 (3)
P 3 (1)

Trial Status

Recruiting2
Enrolling By Invitation2
Not Yet Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT07855640RecruitingPrimary

Anti-PD-1 in Combination With Systemic Chemotherapy With Nab-paclitaxel Intraperitoneal Infusion for Untreated Advanced Gastric Cancer With Malignant Ascites

NCT07304271Phase 3RecruitingPrimary

Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastasis

NCT07517419Phase 2Enrolling By InvitationPrimary

PIPAC in Gastric Peritoneal Metastasis

NCT07304258Phase 2Not Yet RecruitingPrimary

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

NCT06487715Phase 2Enrolling By InvitationPrimary

Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis

Showing all 5 trials

Research Network

Activity Timeline